NCT05785390View on ClinicalTrials.gov

Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.

PHASE2TerminatedINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

February 22, 2023

Primary Completion Date

May 9, 2025

Study Completion Date

May 9, 2025

Conditions
COVID-19
Interventions
DRUG

NP-101

NP-101 is an organically derived, GMP manufactured product covered under IND #152687.

OTHER

Placebo

Identical placebo

Trial Locations (4)

33142

L&A Morales Healthcare/ Enrique Villa, MD Principal Investigator, Miami

60402

Research Network America, Berwyn

77074

Clinical Trial Network, Houston

77584

Pearland Family Wellness Clinic, Pearland

Sponsors
All Listed Sponsors
lead

Novatek Pharmaceuticals

INDUSTRY

NCT05785390 - Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive. | Biotech Hunter | Biotech Hunter